ZEUS
The Zometa European Study (ZEUS) study is an intergroup trial sponsored by the European Association of Urology in collaboration with the SPCG and the AUO. It is the first randomized clinical trial conducted by the European Association of Urology. The aim is to randomise a total of 1300 patients. More than 150 centres in 13 countries in Europe are participating. The centres have been selected to contribute an average of 10 patients in two years time.
Objective: The main objective of this clinical trial is to assess the efficacy and tolerability of zoledronic acid administered every 3 months in high risk prostate cancer patients as compared to best supportive care in preventing bone metastases.
Zoledronic acid (Zometa®)
Zoledronic acid (Zometa®) is a third-generation nitrogen-containing bisphosphonate which is being developed because of its improved therapeutic window in animal models of benign and malignant bone disorders and increased potency relative to other bisphosphonates including the direct inhibition of prostate cancer cells.
Zometa has been approved in Europe and the US for the treatment of bone metastases in a broad range of tumors and for the treatment of malignancy-related hypercalcemia.
It is expected that Zometa® will show its potential in preventing hormone therapy-induced bone loss in addition to the prevention of bone metastases.
Any prostate cancer patient without bone metastases and compliant with one or more of the following criteria is potentially eligible:
- PSA > 20 ng/ml at diagnosis
- pN+
- Gleason 8-10
Read more on the Zeus study....
